Dr. Mark Nathan, MD

Interventional Cardiology Walnut Creek, CA Male
NPI: 1013947670
Total Payments
$338,605
2021 Payments
$38,528
Companies
18
Transactions
497
Medicare Patients
4,806
Medicare Billing
$704,495

Payment Breakdown by Category

Other$276,413 (81.6%)
Travel$38,964 (11.5%)
Food & Beverage$12,993 (3.8%)
Consulting$10,125 (3.0%)
Education$110.06 (0.0%)

Payments by Nature

Nature of Payment Amount Transactions Share
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $276,413 141 81.6%
Travel and Lodging $38,964 131 11.5%
Food and Beverage $12,993 214 3.8%
Consulting Fee $10,125 7 3.0%
Education $110.06 4 0.0%

Top Paying Companies

Company Total Records Latest Year
Boehringer Ingelheim Pharmaceuticals, Inc. $172,087 188 $0 (2021)
Amgen Inc. $75,438 119 $0 (2021)
Lilly USA, LLC $43,866 71 $0 (2021)
Astellas Pharma US Inc $33,668 30 $0 (2020)
AstraZeneca Pharmaceuticals LP $6,736 14 $0 (2021)
Medtronic Vascular, Inc. $3,094 26 $0 (2019)
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $1,789 8 $0 (2019)
PFIZER INC. $351.40 9 $0 (2019)
BIOTRONIK INC. $316.98 12 $0 (2020)
HeartFlow, Inc. $284.12 4 $0 (2020)

Payment History by Year

Year Amount Transactions Top Company
2021 $38,528 41 Boehringer Ingelheim Pharmaceuticals, Inc. ($32,957)
2020 $23,129 33 Lilly USA, LLC ($11,154)
2019 $96,587 140 Boehringer Ingelheim Pharmaceuticals, Inc. ($46,318)
2018 $58,766 81 Boehringer Ingelheim Pharmaceuticals, Inc. ($50,193)
2017 $121,595 202 Amgen Inc. ($60,869)

All Payment Transactions

497 individual payment records from CMS Open Payments — Page 1 of 20

Date Company Product Nature Form Amount Type
11/10/2021 Boehringer Ingelheim Pharmaceuticals, Inc. JARDIANCE (Drug) Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $3,375.00 General
Category: DIABETES
11/10/2021 Boehringer Ingelheim Pharmaceuticals, Inc. JARDIANCE (Drug) Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $2,700.00 General
Category: DIABETES
11/10/2021 Boehringer Ingelheim Pharmaceuticals, Inc. JARDIANCE (Drug) Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $1,687.50 General
Category: DIABETES
11/10/2021 Boehringer Ingelheim Pharmaceuticals, Inc. JARDIANCE (Drug) Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $900.00 General
Category: DIABETES
11/10/2021 Boehringer Ingelheim Pharmaceuticals, Inc. JARDIANCE (Drug) Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $900.00 General
Category: DIABETES
11/04/2021 Boehringer Ingelheim Pharmaceuticals, Inc. JARDIANCE (Drug) Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $1,687.50 General
Category: DIABETES
11/04/2021 Boehringer Ingelheim Pharmaceuticals, Inc. JARDIANCE (Drug) Travel and Lodging In-kind items and services $61.75 General
Category: DIABETES
11/04/2021 Boehringer Ingelheim Pharmaceuticals, Inc. JARDIANCE (Drug) Travel and Lodging In-kind items and services $61.44 General
Category: DIABETES
10/28/2021 Boehringer Ingelheim Pharmaceuticals, Inc. JARDIANCE (Drug) Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $2,475.00 General
Category: DIABETES
10/28/2021 Boehringer Ingelheim Pharmaceuticals, Inc. JARDIANCE (Drug) Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $2,475.00 General
Category: DIABETES
10/28/2021 Boehringer Ingelheim Pharmaceuticals, Inc. JARDIANCE (Drug) Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $900.00 General
Category: DIABETES
10/21/2021 Boehringer Ingelheim Pharmaceuticals, Inc. JARDIANCE (Drug) Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $3,150.00 General
Category: DIABETES
10/21/2021 Boehringer Ingelheim Pharmaceuticals, Inc. JARDIANCE (Drug) Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $900.00 General
Category: DIABETES
10/21/2021 Boehringer Ingelheim Pharmaceuticals, Inc. JARDIANCE (Drug) Food and Beverage In-kind items and services $103.55 General
Category: DIABETES
10/21/2021 Boehringer Ingelheim Pharmaceuticals, Inc. JARDIANCE (Drug) Travel and Lodging In-kind items and services $86.44 General
Category: DIABETES
10/21/2021 Boehringer Ingelheim Pharmaceuticals, Inc. JARDIANCE (Drug) Food and Beverage In-kind items and services $36.00 General
Category: DIABETES
10/20/2021 Boehringer Ingelheim Pharmaceuticals, Inc. JARDIANCE (Drug) Travel and Lodging In-kind items and services $2,039.96 General
Category: DIABETES
10/20/2021 Boehringer Ingelheim Pharmaceuticals, Inc. JARDIANCE (Drug) Travel and Lodging In-kind items and services $290.02 General
Category: DIABETES
10/20/2021 Boehringer Ingelheim Pharmaceuticals, Inc. JARDIANCE (Drug) Food and Beverage In-kind items and services $116.00 General
Category: DIABETES
10/20/2021 Boehringer Ingelheim Pharmaceuticals, Inc. JARDIANCE (Drug) Food and Beverage In-kind items and services $19.08 General
Category: DIABETES
10/13/2021 Boehringer Ingelheim Pharmaceuticals, Inc. JARDIANCE (Drug) Food and Beverage In-kind items and services $123.57 General
Category: DIABETES
10/07/2021 Boehringer Ingelheim Pharmaceuticals, Inc. JARDIANCE (Drug) Food and Beverage In-kind items and services $123.89 General
Category: DIABETES
09/28/2021 Boehringer Ingelheim Pharmaceuticals, Inc. JARDIANCE (Drug) Travel and Lodging In-kind items and services $1,265.87 General
Category: DIABETES
09/28/2021 Boehringer Ingelheim Pharmaceuticals, Inc. JARDIANCE (Drug) Food and Beverage In-kind items and services $120.89 General
Category: DIABETES
09/15/2021 Lilly USA, LLC JARDIANCE (Drug) Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $1,350.00 General
Category: Diabetes
123…20»

Medicare Billing by Year

Year Procedures Beneficiaries Services Submitted Medicare Paid
2021 30 2,285 3,743 $1.5M $329,173
2020 35 2,521 4,121 $1.8M $375,323
Total Patients
4,806
Total Services
7,864
Medicare Billing
$704,495
Procedure Codes
68

All Medicare Procedures & Services

68 procedure records from CMS Medicare Utilization — Page 1 of 3

HCPCS Description Setting Year Patients Services Charges Medicare Paid Ratio
78452 Nuclear medicine study of vessels of heart using drugs or exercise multiple studies Office 2021 175 175 $344,925 $85,961 24.9%
99215 Established patient outpatient visit, total time 40-54 minutes Office 2021 151 210 $106,890 $34,613 32.4%
A9500 Technetium tc-99m sestamibi, diagnostic, per study dose Office 2021 174 348 $144,768 $34,386 23.8%
J2785 Injection, regadenoson, 0.1 mg Office 2021 156 624 $124,176 $29,675 23.9%
99214 Established patient outpatient visit, total time 30-39 minutes Office 2021 214 254 $105,918 $25,930 24.5%
99232 Subsequent hospital inpatient care, typically 25 minutes per day Facility 2021 122 222 $56,832 $14,028 24.7%
93306 Ultrasound examination of heart including color-depicted blood flow rate, direction, and valve function Office 2021 89 89 $78,222 $13,525 17.3%
93015 Exercise or drug-induced heart and blood vessel stress test with ekg monitoring, physician supervision, interpretation, and report Office 2021 173 173 $86,673 $10,666 12.3%
99223 Initial hospital inpatient care, typically 70 minutes per day Facility 2021 60 60 $43,260 $10,620 24.5%
93297 Remote evaluations of implantable heart and blood vessel monitor system with qualified health care professional analysis, review, and report, up to 30 days Office 2021 47 335 $31,825 $7,861 24.7%
33208 Insertion of new or replacement of permanent pacemaker including upper and lower chamber electrodes Facility 2021 16 16 $36,352 $7,496 20.6%
99233 Subsequent hospital inpatient care, typically 35 minutes per day Facility 2021 42 71 $25,844 $6,451 25.0%
93296 Remote evaluations of single, dual, or multiple lead pacemaker system or implantable defibrillator system with technician review, support and distribution of results, up to 90 days Office 2021 76 199 $30,049 $5,213 17.3%
93880 Ultrasound scanning of blood flow (outside the brain) on both sides of head and neck Office 2021 24 24 $26,472 $5,085 19.2%
99204 New patient outpatient visit, total time 45-59 minutes Office 2021 36 36 $23,076 $4,664 20.2%
99222 Initial hospital inpatient care, typically 50 minutes per day Facility 2021 35 36 $18,072 $3,981 22.0%
93294 Remote evaluations of single, dual, or multiple lead pacemaker system with qualified health care professional analysis, review, and report, up to 90 days Office 2021 58 146 $18,834 $3,891 20.7%
93000 Routine ekg using at least 12 leads including interpretation and report Office 2021 260 298 $31,588 $3,825 12.1%
99213 Established patient outpatient visit, total time 20-29 minutes Office 2021 49 49 $15,239 $3,529 23.2%
99205 New patient outpatient visit, total time 60-74 minutes Office 2021 18 18 $13,464 $3,305 24.5%
93280 Evaluation, testing, and programming adjustment of permanent dual lead pacemaker system with physician analysis, review, and report Office 2021 30 44 $15,664 $3,070 19.6%
93306 Ultrasound examination of heart including color-depicted blood flow rate, direction, and valve function Facility 2021 45 45 $12,825 $2,915 22.7%
93925 Ultrasound study of arteries and arterial grafts of both legs Office 2021 11 11 $11,165 $2,284 20.5%
93295 Remote evaluations of defibrillator up to 90 days with analysis, review and report Office 2021 18 53 $13,462 $1,646 12.2%
99442 Physician telephone patient service, 11-20 minutes of medical discussion Office 2021 34 35 $10,885 $1,407 12.9%
123»

About Dr. Mark Nathan, MD

Dr. Mark Nathan, MD is a Interventional Cardiology healthcare provider based in Walnut Creek, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/03/2006. The National Provider Identifier (NPI) number assigned to this provider is 1013947670.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Nathan, MD has received a total of $338,605 in payments from pharmaceutical and medical device companies, with $38,528 received in 2021. These payments were reported across 497 transactions from 18 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($276,413).

As a Medicare-enrolled provider, Nathan has provided services to 4,806 Medicare beneficiaries, totaling 7,864 services with total Medicare billing of $704,495. Data is available for 2 years (2020–2021), covering 68 distinct procedure/service records.

Practice Information

  • Specialty Interventional Cardiology
  • Location Walnut Creek, CA
  • Active Since 07/03/2006
  • Last Updated 06/25/2010
  • Taxonomy Code 207RI0011X
  • Entity Type Individual
  • NPI Number 1013947670

Products in Payments

  • JARDIANCE (Drug) $214,137
  • Repatha (Biological) $75,438
  • LEXISCAN (Drug) $12,301
  • FARXIGA (Drug) $6,614
  • Lexiscan (Drug) $3,290
  • LifeVest (Device) $1,789
  • Reveal LINQ (Device) $819.14
  • VYNDAQEL (Drug) $219.05
  • ENTRESTO (Drug) $210.07
  • PRADAXA (Drug) $183.88
  • ANDEXXA (Biological) $132.30
  • Xience V coronary stent system (Device) $128.05
  • BEVYXXA (Drug) $125.37
  • SAMSCA (Drug) $124.14
  • BRILINTA (Drug) $122.37
  • Amplia MRI (Device) $120.00
  • Claria MRI (Device) $112.06
  • ADVANTIO (Device) $58.15
  • SYNERGY (Device) $58.15
  • XARELTO (Drug) $56.71

Explore

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Interventional Cardiology Doctors in Walnut Creek

Andrew Benn, Md, MD

Interventional Cardiology — Payments: $205,294

Interventional Cardiology $205,294

Christopher Wulff, Md, MD

Interventional Cardiology — Payments: $19,495

Interventional Cardiology $19,495

John Krouse, Md, MD

Interventional Cardiology — Payments: $7,578

Interventional Cardiology $7,578

Alexander Meyer, Md, MD

Interventional Cardiology — Payments: $2,057

Interventional Cardiology $2,057

Christopher Forrest, Md, MD

Interventional Cardiology — Payments: $1,122

Interventional Cardiology $1,122

A. William Waibel, Md, MD

Interventional Cardiology — Payments: $675.67

Interventional Cardiology $675.67